Lite Strategy Reports Fiscal 2026 Second Quarter Results

SAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset, today announced financial results for the fiscal 2026 second quarter ended December 31, 2025. During the second quarter, the Company successfully launched its strategic initiative to transform its LTC holdings into a productive reserve asset, utilizing covered call options while also implementing a $25 million stock repurchase program.

GlobeNewsWire • Feb 17, 2026

MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS'

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or the “Company”) today announced that it will change its corporate name to Lite Strategy, Inc., reflecting the Company's expansion into a pioneer in digital asset treasury management. Alongside the rebrand, the Company's ticker symbol on the NASDAQ Stock Market will transition from MEIP to LITS, effective at market open on September 11, 2025. The rebranding to Lite Strategy, Inc. underscores the Company's commitment to building.

Business Wire • Sep 10, 2025

MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or “the Company”) today announced the acquisition of 929,548 Litecoin (LTC) tokens at an average price of $107.58, successfully launching a major institutional treasury strategy with the LTC treasury now valued at approximately $110.4 million as of August 4, 2025. MEI becomes the first U.S.-listed public company to adopt Litecoin as a primary reserve asset, implementing a new strategy built on digital asset infrastructure and lo.

Business Wire • Aug 5, 2025

BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode

[UK, July 24, 2025] - BTC As the blockchain industry enters a new round of market cycle, the multi-currency linkage effect gradually emerges, and the price of BTC today starts to rise at 118875.30. According to foreign media reports such as Investing, with the continuous inflow of US spot ETF funds, the acceleration of technology implementation by the Ethereum Layer 2 Industry Alliance, and the launch of the network upgrade of Dogecoin (DOGE), Bitcoin's "safe-haven attribute" as a market value anchor has once again attracted capital favor, and its network computing power and BTC mining income have increased significantly. Another major positive news this week also boosted BTC confidence: MEI Pharmaceuticals (NASDAQ: MEIP) announced that Litecoin (LTC) will be included in the corporate treasury portfolio and completed the allocation of digital assets worth $100 million, which has aroused the capital market's deep attention to the reserve allocation model of encrypted assets. This behavior not only verifies the trust of mainstream institutions in encrypted assets, but also indirectly drives the prices of major currencies including Bitcoin to rise simultaneously. Hashj made timely adjustments to the market and provided new members with a maximum registration reward of $118 for BTC mining experience.

MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy.

Business Wire • Jul 22, 2025

Why Is MEI Pharma Stock Soaring On Friday?

MEI Pharma, Inc. MEIP stock is trading higher on Friday, with a session volume of 35.64 million compared to the average volume of 29.8K, as per data from Benzinga Pro.

Benzinga • Jul 18, 2025

MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company” or “MEI”) today announced that it has entered into securities purchase agreements for a private investment in public equity (PIPE) for the purchase and sale of 29,239,767 shares of common stock (or pre-funded warrants in lieu thereof) at a price of $3.42 per share, for expected aggregate gross proceeds of approximately $100 million, before deducting placement agent fees and other estimated offering expenses. In connectio.

Business Wire • Jul 18, 2025

MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its third quarter ended March 31, 2025. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company is considering options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockh.

Business Wire • May 13, 2025

MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its st.

Business Wire • Feb 12, 2025

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders.

Business Wire • Nov 12, 2024